SER — Serina Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- $80.61m
- $82.36m
- $0.14m
Annual cashflow statement for Serina Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -12.2 | -10.9 | -8.58 | -10.5 | -14.8 |
| Depreciation | |||||
| Amortisation | |||||
| Non-Cash Items | 1.75 | 1.85 | 1.48 | 4.06 | 5.33 |
| Discontinued Operations | |||||
| Unusual Items | |||||
| Purchased R&D | |||||
| Equity in Net Earnings/Losses | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -0.41 | -0.062 | -0.884 | 0.329 | 1.54 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Accounts Payable | |||||
| Change in Payable / Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -10.2 | -7.82 | -7.86 | -5.94 | -7.8 |
| Capital Expenditures | -0.641 | -0.02 | 0 | — | — |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | 0.28 | — | 0.666 | 0 | -10 |
| Sale of Business | |||||
| Sale/Maturity of Investment | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -0.361 | -0.02 | 0.666 | 0 | -10 |
| Financing Cash Flow Items | — | -0.157 | -0.25 | 0 | — |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 6.26 | 5.96 | 7.25 | 6 | 17.5 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -4.25 | -1.88 | 0.057 | 0.061 | -0.3 |